Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table. Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices. The TRICENTO has an<a href="https://solaci.org/en/2022/03/25/tricento-promising-results-for-severe-tricuspid-valve-regurgitation/" title="Read more" >...</a>
Tricuspid valve: Is Percutaneous Intervention Feasible in Patients with Definite Pacemaker?
Courtesy of Dr. Carlos Fava. As we know, with higher life expectancy comes a significant increase in the use of definite pacemakers, defibrillators and resynchronization devices. Along these lines, the presence of catheters is associated to tricuspid regurgitation, which over time might become severe, leading to cardiac regurgitation and potentially heart failure. This group is<a href="https://solaci.org/en/2020/04/13/tricuspid-valve-is-percutaneous-intervention-feasible-in-patients-with-definite-pacemaker/" title="Read more" >...</a>
PASCAL in Tricuspid Regurgitation with Encouraging Results
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is associated with higher mortality and morbidity, and it most frequently has a functional cause. Furthermore, it has been proven that tricuspid surgery has mortality rates between 8% and 20%. On the other hand, it has been verified that, in the case of left-sided disease affecting the<a href="https://solaci.org/en/2020/01/21/pascal-in-tricuspid-regurgitation-with-encouraging-results/" title="Read more" >...</a>
More Evidence on Tricuspid Valve Repair
While still lacking large-scale randomized trials, evidence is slowly building for transcatheter tricuspid valve repair. This work, presented at the TCT 2019 Congress and simultaneously published in JACC, shows that transcatheter tricuspid valve repair is not only feasible, but also likely to reduce the rates of mortality and heart failure rehospitalization compared with medical therapy alone.<a href="https://solaci.org/en/2019/10/18/more-evidence-on-tricuspid-valve-repair/" title="Read more" >...</a>
TCT 2019 | A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs. Medical Treatment in Patients With Severe Tricuspid Regurgitation
Courtesy of the SBHCI. Discover the results of the this study, presented during TCT Congress 2019. Link to the SBHCI publication HERE Original Title: A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs. Medical Treatment in Patients With Severe Tricuspid Regurgitation. Author of the original title: Maurizio Taramasso. We are interested in your opinion. Please,<a href="https://solaci.org/en/2019/09/30/tct-2019-a-propensity-score-matched-analysis-of-transcatheter-tricuspid-valve-treatment-vs-medical-treatment-in-patients-with-severe-tricuspid-regurgitation/" title="Read more" >...</a>
Physiological and Clinical Changes After Tricuspid Repair
After the recent announcement by the US Food and Drug Administration (FDA) green-lighting transcatheter aortic valve replacement (TAVR) in patients across the whole spectrum, and given the advancements regarding devices already in the market (such as MitraClip) and a variety of pulmonary valves, there is only one territory left to conquer: the long forgotten tricuspid<a href="https://solaci.org/en/2019/08/30/physiological-and-clinical-changes-after-tricuspid-repair/" title="Read more" >...</a>
Impact of Edge to Edge Transcatheter Tricuspid Valve Repair
Reducing tricuspid regurgitation with transcatheter valve repair is associated to improved liver function, which is often ignored by many cardiologists. This is especially true in cases with deteriorated liver function prior valve repair. Instead, kidney function did not show any changes. Transcatheter tricuspid valve repair seems attractive especially in patients with liver failure. Edge to<a href="https://solaci.org/en/2019/08/27/impact-of-edge-to-edge-transcatheter-tricuspid-valve-repair/" title="Read more" >...</a>
Surgery to Improve Survival in Isolated Tricuspid Regurgitation
Patients with isolated tricuspid regurgitation (i.e., who have no associated left-sided valve disease) are frequently treated conservatively. In many cases, valve disease is highly symptomatic, even with the optimization of medical treatment; however, an invasive strategy is seldom proposed. The aim of this work was to measure the impact of surgery on isolated tricuspid regurgitation<a href="https://solaci.org/en/2019/08/26/surgery-to-improve-survival-in-isolated-tricuspid-regurgitation/" title="Read more" >...</a>
EuroPCR 2019 | TRILUMINATE: Tricuspid Repair with Clip Improves Regurgitation and Quality of Life
Transcatheter therapy offers a promise for a largely forgotten valve given the lack of therapeutic options. Percutaneous edge-to-edge repair with clip seems to offer some hope to patients with tricuspid regurgitation according to the TRILUMINATE. At 30 days, transcatheter repair with clip significantly reduced tricuspid regurgitation at least in one grade in most patients, which<a href="https://solaci.org/en/2019/05/24/europcr-2019-triluminate-tricuspid-repair-with-clip-improves-regurgitation-and-quality-of-life/" title="Read more" >...</a>
Promising Results for Tricuspid Repair
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is more common than we thought. Around 1.6 million people in the US and over 3 million in Europe experience significant TR. It usually has a functional cause and its negative impact on patient prognosis is strong. Its surgical treatment is challenging, and it is important that its resolution<a href="https://solaci.org/en/2019/05/03/promising-results-for-tricuspid-repair/" title="Read more" >...</a>